✨ Free AI Report
Amicus Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Amicus Therapeutics, Inc.
Research Preview

Amicus Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. In 2024, Amicus Therapeutic...

Analyst-debate audio for Amicus Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Amicus Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Amicus Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Strong rare disease biotech with accelerating revenue growth, validated products, and strategic acquisition upside at...

Read the full analyst-debate transcript →
Industry Biotechnology - Rare/Orphan Diseases, Lysosomal Storage Disorders
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Amicus Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Amicus Therapeutics, Inc. Overview

Pro stress-test →

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. In 2024, Amicus Therapeutics' revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. The company is being acquired by BioMarin Pharmaceutical for $4.8 billion, with closure expected in Q2 2026.

Strategic Profile

Pro stress-test →

The company's commercial products consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. The company expanded globally with Japan approval for Pompe therapy and plans to launch in 10 new European markets. Pipeline highlights include DMX-200's Phase 3 trial for FSGS and gene therapy advancements, supported by Teva's patent settlement ensuring Galafold's U.S. exclusivity until 2037.

Competitive Landscape

Pro stress-test →

BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market with an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. Amicus competes in rare metabolic diseases with a differentiated portfolio including the only approved oral precision medicine for amenable Fabry disease variants and emerging therapies for Pompe disease and other genetic conditions.

Industry Context

Amicus Therapeutics, Inc. operates in Biotechnology - Rare/Orphan Diseases, Lysosomal Storage Disorders.

Key facts

Founded: 2002 · Headquarters: Princeton, NJ · Employees: 499 · Revenue: $528M (2024) · Market cap: $0.7B (at $14.50/share acquisition price)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Amicus Therapeutics, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Amicus Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

VimizimEnzyme replacement therapy for rare disease→CerdelgaTreatment for Gaucher disease→Enzyme Replacement TherapiesLysosomal storage disorder treatments→

Compare Amicus Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Amicus Therapeutics, Inc. operates in Biotechnology - Rare/Orphan Diseases, Lysosomal Storage Disorders. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Rare/Orphan Diseases, Lysosomal Storage Disorders research →
NEW · MCP server

Ask your AI assistant about Amicus Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Amicus Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Amicus Therapeutics, Inc. do this quarter?”
“Is Amicus Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Amicus Therapeutics, Inc. do?+
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. In 2024, Amicus Therapeutic...
What is Amicus Therapeutics, Inc.'s Cyborg Score?+
Amicus Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Amicus Therapeutics, Inc.'s main competitors?+
Named competitors include Vimizim, Cerdelga, Enzyme Replacement Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Amicus Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Amicus Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Amicus Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.